Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms

doi:10.3389/fnins.2020.602697

科研成果详情

题名	Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms
作者	Ren, Xiangpeng1,2,3; Chen, Jiang-Fan1,2
发表日期	2020-12-17
发表期刊	FRONTIERS IN NEUROSCIENCE 影响因子和分区
语种	英语
原始文献类型	Review
关键词	caffeine Parkinson’ s disease α -synuclein adenosine A(2A) receptor autophagy gut microbiota
其他关键词	ADENOSINE A(2A) RECEPTOR ; GUT-BRAIN AXIS ; ALPHA-SYNUCLEIN ; COGNITIVE IMPAIRMENT ; COFFEE CONSUMPTION ; ALZHEIMERS-DISEASE ; NONMOTOR SYMPTOMS ; AUTOPHAGIC FLUX ; WORKING-MEMORY ; ANIMAL-MODELS
摘要	Parkinson's disease (PD) is the second most common neurodegenerative disorder, characterized by dopaminergic neurodegeneration, motor impairment and non-motor symptoms. Epidemiological and experimental investigations into potential risk factors have firmly established that dietary factor caffeine, the most-widely consumed psychoactive substance, may exerts not only neuroprotective but a motor and non-motor (cognitive) benefits in PD. These multi-benefits of caffeine in PD are supported by convergence of epidemiological and animal evidence. At least six large prospective epidemiological studies have firmly established a relationship between increased caffeine consumption and decreased risk of developing PD. In addition, animal studies have also demonstrated that caffeine confers neuroprotection against dopaminergic neurodegeneration using PD models of mitochondrial toxins (MPTP, 6-OHDA, and rotenone) and expression of alpha-synuclein (alpha-Syn). While caffeine has complex pharmacological profiles, studies with genetic knockout mice have clearly revealed that caffeine's action is largely mediated by the brain adenosine A(2A) receptor (A(2A)R) and confer neuroprotection by modulating neuroinflammation and excitotoxicity and mitochondrial function. Interestingly, recent studies have highlighted emerging new mechanisms including caffeine modulation of alpha-Syn degradation with enhanced autophagy and caffeine modulation of gut microbiota and gut-brain axis in PD models. Importantly, since the first clinical trial in 2003, United States FDA has finally approved clinical use of the A(2A)R antagonist istradefylline for the treatment of PD with OFF-time in Sept. 2019. To realize therapeutic potential of caffeine in PD, genetic study of caffeine and risk genes in human population may identify useful pharmacogenetic markers for predicting individual responses to caffeine in PD clinical trials and thus offer a unique opportunity for personalized medicine in PD.
资助项目	National Key Research and Development Program of China [2016YFC1306600]; Zhejiang Provincial Natural Science FoundationNatural Science Foundation of Zhejiang Province [LY18H090012]; Wenzhou Science and Technology Program [Y20190083]
出版者	FRONTIERS MEDIA SA
出版地	LAUSANNE
ISSN	1662-4548
EISSN	1662-453X
卷号	14 页码:602697
DOI	10.3389/fnins.2020.602697
页数	12
WOS类目	Neurosciences
WOS研究方向	Neurosciences & Neurology
WOS记录号	WOS:000603614800001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	33390888
PMC记录号	PMC7773776
SCOPUSEID	2-s2.0-85098621260
通讯作者地址	[Ren, Xiangpeng]Molecular Neuropharmacology Lab,School of Optometry and Ophthalmology,Wenzhou Medical University,Wenzhou,China ; [Chen, Jiang-Fan]Molecular Neuropharmacology Lab,School of Optometry and Ophthalmology,Wenzhou Medical University,Wenzhou,China ; [Ren, Xiangpeng]State Key Laboratory of Ophthalmology,Optometry and Visual Science,Wenzhou,China ; [Chen, Jiang-Fan]State Key Laboratory of Ophthalmology,Optometry and Visual Science,Wenzhou,China ; [Ren, Xiangpeng]Department of Biochemistry,Medical College,Jiaxing University,Jiaxing,China
Scopus学科分类	Neuroscience (all)
引用统计	被引频次：32[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/5786
专题	眼视光学院（生物医学工程学院）、附属眼视光医院_分子生物学实验室
通讯作者	Ren, Xiangpeng; Chen, Jiang-Fan
作者单位	1.Molecular Neuropharmacology Lab,School of Optometry and Ophthalmology,Wenzhou Medical University,Wenzhou,China; 2.State Key Laboratory of Ophthalmology,Optometry and Visual Science,Wenzhou,China; 3.Department of Biochemistry,Medical College,Jiaxing University,Jiaxing,China
第一作者单位	温州医科大学
通讯作者单位	温州医科大学
第一作者的第一单位	温州医科大学
推荐引用方式 GB/T 7714	Ren, Xiangpeng,Chen, Jiang-Fan. Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms[J]. FRONTIERS IN NEUROSCIENCE,2020,14:602697.
APA	Ren, Xiangpeng, & Chen, Jiang-Fan. (2020). Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms. FRONTIERS IN NEUROSCIENCE, 14, 602697.
MLA	Ren, Xiangpeng,et al."Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms".FRONTIERS IN NEUROSCIENCE 14(2020):602697.